Jasper Therapeutics: Upcoming Investor Conferences and Insights

Insights on Jasper Therapeutics' Upcoming Events

Jasper Therapeutics, Inc. (NASDAQ: JSPR) is making significant strides in the biotechnology sector as it approaches several key investor conferences. With a focus on briquilimab, an innovative antibody therapy designed to target c-Kit (CD117), Jasper is dedicated to tackling mast cell-driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.

Details of the Investor Conferences

Stifel 2024 Healthcare Conference

The company is scheduled to attend the Stifel 2024 Healthcare Conference, slated for November 18–19. Jasper will be making a presentation on November 18 at 9:45 a.m. ET, utilizing a fireside chat format to engage with investors.

Jefferies London Healthcare Conference 2024

Following Stifel, Jasper will participate in the Jefferies London Healthcare Conference from November 19 to November 21. This conference provides a platform for Jasper to showcase its advancements to a broader audience, enhancing visibility within the investment community.

7th Annual Evercore ISI HealthCONx Conference

Additionally, Jasper will partake in the 7th Annual Evercore ISI HealthCONx Conference happening from December 3 to December 5. The company's presentation is scheduled for December 3 at 3:25 p.m. ET, also delivered in a fireside chat format.

Live Webcast Availability

For those unable to attend the conferences in person, Jasper will provide live webcasts of all presentations. These webcasts will be accessible through the Events & News section on Jasper's Investor Relations website. Moreover, archived replays of each presentation will be available for 30 days, ensuring that the telemetry of these discussions reaches a wider audience.

About Jasper Therapeutics

Jasper Therapeutics is at the forefront of developing briquilimab, a monoclonal antibody targeting c-Kit (CD117). This therapeutic is crafted to provide relief for chronic mast and stem cell diseases. Not only does briquilimab address chronic urticaria and asthma, but it also serves as a vital conditioning agent for stem cell transplants aimed at rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA), and severe combined immunodeficiency (SCID).

Jasper's approach has already shown considerable results, with an established efficacy and safety profile in over 160 dosed participants and healthy volunteers. Remarkably, clinical outcomes in CIndU, SCID, acute myeloid leukemia, myelodysplastic syndromes, FA, and SCD highlight the immense potential of briquilimab.

Frequent Inquiries about Jasper Therapeutics

What is briquilimab?

Briquilimab is a monoclonal antibody developed by Jasper Therapeutics that targets c-Kit (CD117) to treat various mast cell-driven diseases, such as chronic urticaria and asthma.

When will Jasper present at investor conferences?

Jasper will present at multiple conferences, including the Stifel 2024 Healthcare Conference on November 18 and the Evercore ISI HealthCONx Conference on December 3.

Where can I find the live webcasts of the presentations?

Live webcasts of Jasper’s presentations can be found on the Events & News section of the company's Investor Relations website.

Is briquilimab approved for public use?

As of now, briquilimab is still in clinical development, demonstrating efficacy and safety through trials.

Who can I contact for more information about Jasper Therapeutics?

For investor inquiries, you can contact Joyce Allaire at LifeSci Advisors or Alex Gray at Jasper Therapeutics. Their contact information is available on the Investor Relations page.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.